

The last rites for cystoscopy?

Poster Session 09

Friday, 24 March
12:30 - 14:00

Location: Room Vienna, North Hall (Level 1)

Chairs: P. Black, Vancouver (CA)
R.T. Bryan, Birmingham (GB)

Aims and objectives of this session

To understand where TCC molecular diagnostics is heading. Ready for prime time or more hype than hope?

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

117

Validation of a mRNA-based urine test for bladder cancer detection in patients with hematuria

By: Van Valenberg F.J.P.¹, Bridge J.A.², Mayne D.³, Beqaj S.⁴, Sexton W.J.⁵, Lotan Y.⁶, Weizer A.Z.⁷, Jansz G.K.⁸, Stenzl A.⁹, Danella J.F.¹⁰, Shepard B.R.¹¹, Cline K.J.¹², Williams M.B.¹³, Montgomery T.¹⁴, David R.D.¹⁵, Harris R.G.¹⁶, Klein E.W.¹⁷, Bradford T.J.¹⁸, Wolk F.N.¹⁹, Westenfelder K.R.²⁰, Trainer A.F.²¹, Richardson T.A.²², Witjes J.A.¹

Institutes:¹Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ²University of Nebraska Medical Center, Departments of Pathology/Microbiology, Pediatrics and Orthopaedic Surgery, Omaha, United States of America, ³Sacred Heart Hospital, Molecular Laboratory, Pensacola, United States of America, ⁴Pathology Inc., Clinical Laboratory, Torrance, United States of America, ⁵Moffitt Cancer Center, Genitourinary Oncology and Oncologic Sciences, Tampa, United States of America, ⁶University of Texas Southwestern, Dept. of Urology, Dallas, United States of America, ⁷University of Michigan Hospital, Dept. of Urology, Ann Arbor, United States of America, ⁸G. Kenneth Jansz MPC, Private Practice, Burlington, Canada, ⁹University of Tübingen, Dept. of Urology, Tübingen, Germany, ¹⁰Geisinger Health System, Dept. of Urology, Danville, United States of America, ¹¹Urological Surgeons of Long Island, PLLC, Private Practice, Garden City, United States of America, ¹²Regional Urology, Private Practice, Shreveport, United States of America, ¹³Urology of Virginia, Private Practice, Virginia Beach, United States of America, ¹⁴Kansas City Urology Care, Private Practice, Overland Park, United States of America, ¹⁵Skyline Urology, Private Practice, Torrance, United States of America, ¹⁶UroPartners, Private Practice, Melrose Park, United States of America, ¹⁷Idaho Urologic Institute, Private Practice, Meridian, United States of America, ¹⁸Virginia Urology, Private Practice, Richmond, United States of America, ¹⁹Skyline Urology, Private Practice, Sherman Oaks, United States of America, ²⁰Five Valleys Urology, Private Practice, Missoula, United States of America, ²¹Adult and Pediatric Urology & Urogynecology, Private Practice, Omaha, United States of America, ²²Wichita Urology Group, Private Practice, Wichita, United States of America

118

Does smoking influence the performance of urine markers in the diagnosis of urothelial carcinoma?

By: Schnürer S., Hennenlotter J., Dockter K., Rausch S., Stenzl A., Todenhöfer T.

Institutes: Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany

119

Performance characteristics of a mRNA-based urine test for the detection of bladder cancer recurrence

By: Van Valenberg F.J.P.¹, Bridge J.A.², Mayne D.⁴, Beqaj S.⁵, Sexton W.J.⁶, Lotan Y.⁷, Weizer A.Z.⁸, Jansz G.K.⁹, Stenzl A.¹⁰, Danella J.F.³, Shepard B.R.¹¹, Cline K.J.¹², Williams M.B.¹³, Montgomery T.¹⁴, David R.D.¹⁵, Harris R.G.¹⁶, Klein E.W.¹⁷, Bradford T.J.¹⁸, Wolk F.N.¹⁹, Westenfelder K.R.²⁰, Trainer A.F.²¹, Richardson T.A.²², Witjes J.A.¹

Institutes:¹Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ²University of Nebraska Medical Center, Dept. of Pathology/Microbiolog, Pediatrics and Orthopaedic Surgery, Omaha, United States of America, ³Geisinger Health System, Dept. of Urology, Danville, United States of

America, ⁴Sacred Heart Hospital, Molecular Laboratory, Pensacola, United States of America, ⁵ Pathology Inc., Clinical Laboratory, Torrance, United States of America, ⁶Moffitt Cancer Center, Genitourinary Oncology and Oncologic Sciences, Tampa, United States of America, ⁷University of Texas Southwestern, Dept. of Urology, Dallas, United States of America, ⁸University of Michigan Hospital, Dept. of Urology, Ann Arbor, United States of America, ⁹G. Kenneth Jansz MPC, , Burlington, Canada, ¹⁰University of Tübingen, Dept. of Urology, Tübingen, Germany, ¹¹Urological Surgeons of Long Island, PLLC, , Garden City, United States of America, ¹²Regional Urology, , Shreveport, United States of America, ¹³Urology of Virginia, , Virginia Beach, United States of America, ¹⁴Kansas City Urology Care, Overland Park, United States of America, ¹⁵Skyline Urology, , Torrance, United States of America, ¹⁶UroPartners, , Melrose Park, United States of America, ¹⁷Idaho Urologic Institute, , Meridian, United States of America, ¹⁸Virginia Urology, , Richmond, United States of America, ¹⁹Skyline Urology, , Sherman Oaks, United States of America, ²⁰Five Valleys Urology, , Missoula, United States of America, ²¹Adult and Pediatric Urology & Urogynecology, , Omaha, United States of America, ²²Wichita Urology Group, , Wichita, United States of America

- 120 **Non invasive prediction of recurrences in bladder cancer by detecting TERT promoter mutations in urine**
By: Kara N.¹, Descotes F.², Decaussin Petrucci M.², Piaton E.², Geiguer F.², Rodriguez-Lafrasse C.², Terrier J.E.¹, Lopez J.², Ruffion A.¹
Institutes:¹Centre Hospitalier Lyon-Sud, Dept. of Urology, Pierre-Bénite, France, ²Centre Hospitalier Lyon-Sud, Dept. of Molecular Biology and Biochemistry, Pierre-Bénite, France
- 121 **Multiplex proximity extension assay of 425 candidate biomarkers in the sera of bladder cancer patients: Correlation with stage and outcome**
By: Ward D.¹, Gordon N.¹, Abbotts B.², James N.³, Zeegers M.⁴, Cheng K.K.⁵, Bryan R.¹
Institutes:¹University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom, ²University of Birmingham, Institute Of Cancer And Genomic Sciences, Birmingham, United Kingdom, ³University of Warwick, Clinical Trials Unit, Warwick, United Kingdom, ⁴University of Maastricht, Dept. of Complex Genetics, Birmingham, United Kingdom, ⁵University of Birmingham, School of Health and Population Sciences, Birmingham, United Kingdom
- 122 **Non-invasive diagnosis and monitoring of bladder cancer utilizing high-throughput genome sequencing on urine sediment**
By: Liu H., Lin T., He W., Wang B., Xu K., Han J., Zheng J., Huang J.
Institutes:Sun Yat-Sen Memorial Hospital, Dept. of Urology, Guangzhou, China
- 123 **Method of detecting bladder cancer by optical analysis of bodily fluids**
By: Rabah D.
Institutes:College of Medicine, King Saud University, Dept. of Surgery, Riyadh, Saudi Arabia
- 124 **Urethral wash cytology accuracy in the diagnosis of asymptomatic urethral recurrence after radical cystectomy for urothelial bladder cancer**
By: Manica M.¹, Naspro R.¹, Pellucchi F.¹, Rocchini L.¹, Roscigno M.¹, Chinaglia D.², Da Pozzo L.F.¹
Institutes:¹Papa Giovanni Xxiii Hospital, Dept. of Urology, Bergamo, Italy, ²Papa Giovanni Xxiii Hospital, Dept. of Pathology, Bergamo, Italy
- 125 **Diagnosis and prediction of recurrent bladder cancer by urinary DNA methylation analysis: Multicenter prospective study**
By: Shindo T.¹, Shimizu T.¹, Nishiyama N.¹, Niinuma T.², Kitajima H.², Kai M.², Shinkai N.¹, Itoh N.³, Tanaka T.¹, Suzuki H.², Masumori N.¹
Institutes:¹Sapporo Medical University School of Medicine, Dept. of Urology, Sapporo, Japan, ²Sapporo Medical University School of Medicine, Dept. of Molecular Biology, Sapporo, Japan, ³NTT East Corporation Sapporo Hospital, Dept. of Urology, Sapporo, Japan
- 126 **Urine-based diagnostics of bladder tumours through volatile organic compounds: A pilot study comparing two detection systems**

By: Heers H.¹, Gut J.¹, Hegele A.¹, Hofmann R.¹, Boeselt T.², Hattesoehl A.², Baumbach J.³, Koczulla A.R.²

Institutes:¹Philipps-Universität Marburg, Dept. of Urology and Paediatric Urology, Marburg, Germany, ²Philipps-Universität Marburg, Dept. of Pneumology, Marburg, Germany, ³Reutlingen University, Dept. of Applied Chemistry, Reutlingen, Germany

127

Effect of contemporary health screening not focused on bladder cancer on diagnosis of bladder urothelial carcinoma

By: Suh Y.S., Sung H.H., Jeon H.G., Jeong B.C., Seo S.I., Lee H.M., Choi H.Y., Jeong J., Lee C.U., Jeon S.S.

Institutes:Samsung Medical Center, Sungkyunkwan University School of Medicine, Dept. of Urology, Seoul, South Korea

128

Molecular tumour grading and classification of non muscle invasive bladder cancer based on whole transcriptome analysis

By: Zlotta A.R.¹, Shen J.², Noon A.³, Jiang H.⁴, Kuk C.¹, Ni R.⁵, Sukhu B.⁵, Chan K.², Erlich A.¹, Roupret M.⁶, Seisen T.⁶, Comparat E.⁷, Sweet J.⁸, Kulkarni G.S.⁹, Fleshner N.E.⁹, Azad A.⁵, Van Der Kwast T.H.⁸, Wrana J.L.²

Institutes:¹Mount Sinai Hospital, Dept. of Surgery (urology), Toronto, Canada, ²Mount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada, ³University of Sheffield, Dept. of Urology, Sheffield, United Kingdom, ⁴University Health Network, Dept. of Statistics, Toronto, Canada, ⁵Mount Sinai Hospital, Dept. of Pathology and Laboratory Medicine, Toronto, Canada, ⁶Groupe Hospitalier La Pitié-Salpêtrière, Université Pierre Et Marie Curie, Dept. of Urology, Paris, France, ⁷Groupe Hospitalier La Pitié-Salpêtrière, Université Pierre Et Marie Curie, Dept. of Pathology, Paris, France, ⁸Toronto General Hospital, University Health Network, Dept. of Pathology, Toronto, Canada, ⁹Princess Margaret Cancer Centre, University Health Network, Dept. of Surgical Oncology, Urology, Toronto, Canada

129

Significance of serum n-glycan profiling as a diagnostic biomarker in urothelial carcinoma

By: Oikawa M.¹, Hatakeyama S.¹, Yoneyma T.², Tobisawa Y.¹, Narita T.¹, Yamamoto H.¹, Hashimoto Y.², Koie T.¹, Narita S.³, Sasaki A.⁴, Tsuchiya N.⁵, Habuchi T.³, Takahashi I.⁶, Nakaji S.⁶, Ohyama C.¹

Institutes:¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Hirosaki University Graduate School of Medicine, Dept. of Advanced Transplant and Regenerative Medicine, Hirosaki, Japan, ³Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, ⁴Tsugaru General Hospital, Dept. of Urology, Tsugaru, Japan, ⁵Yamagata University Graduate School of Medicine, Dept. of Urology, Yamagata, Japan, ⁶Hirosaki University School of Medicine, Dept. of Social Medicine, Hirosaki, Japan

130

Concurrent bladder tumours in patients undergoing photodynamic diagnostic ureterorenoscopy: How many lesions are missed under white light?

By: Zreik A.¹, Kata S.G.², Ahmad S.², Chlosta P.L.³, Aboumarzouk O.M.¹

Institutes:¹Queen Elizabeth University Hospital, Dept. of Urology, Glasgow, United Kingdom, ²Ninewells Hospital, Dept. of Urology, Dundee, United Kingdom, ³Jagiellonian University, Dept. of Urology, Cracow, Poland

13:49 - 13:56

Last word on the last rite

P. Black, Vancouver (CA)